Table 2.
Linear Regression Models Exploring the Association of Glucose (per mg/dL) and Insulin (per μU/mL) Measurements From OGTT With Midthigh Muscle CSA (mm2), Standardized to Body Weight (kg), Among Adults Without Diabetes
Model 1, Demographics* |
Model 2, Height* |
Model 3, Physical Activity* |
Model 4, Neuropathy* |
|||||
β ± SE | p | β ± SE | p | β ± SE | p | β ± SE | p | |
Glucose | ||||||||
Fasting | −0.51 ± 0.11 | <.001 | −0.53 ± 0.11 | <.001 | −0.51 ± 0.11 | <.001 | −0.48 ± 0.12 | <.001 |
5 min | −0.22 ± 0.08 | .005 | −0.23 ± 0.08 | .003 | −0.20 ± 0.08 | .01 | −0.16 ± 0.09 | .07 |
10 min | −0.11 ± 0.06 | .07 | −0.12 ± 0.06 | .05 | −0.10 ± 0.06 | .12 | −0.09 ± 0.07 | .19 |
15 min | −0.14 ± 0.05 | .009 | −0.15 ± 0.05 | .005 | −0.12 ± 0.05 | .02 | −0.11 ± 0.06 | .06 |
20 min | −0.11 ± 0.04 | .02 | −0.12 ± 0.05 | .01 | −0.10 ± 0.05 | .03 | −0.09 ± 0.05 | .06 |
40 min | −0.11 ± 0.03 | <.001 | −0.12 ± 0.03 | <.001 | −0.11 ± 0.03 | <.001 | −0.10 ± 0.03 | .005 |
60 min | −0.08 ± 0.02 | .001 | −0.09 ± 0.02 | <.001 | −0.09 ± 0.02 | <.001 | −0.08 ± 0.03 | .003 |
80 min | −0.08 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 | −0.09 ± 0.03 | <.001 |
100 min | −0.09 ± 0.03 | <.001 | −0.11 ± 0.03 | <.001 | −0.11 ± 0.03 | <.001 | −0.09 ± 0.03 | .002 |
120 min | −0.11 ± 0.03 | <.001 | −0.13 ± 0.03 | <.001 | −0.12 ± 0.03 | <.001 | −0.10 ± 0.04 | .002 |
Insulin | ||||||||
Fasting | −0.77 ± 0.13 | <.001 | −0.73 ± 0.13 | <.001 | −0.71 ± 0.13 | <.001 | −0.60 ± 0.15 | <.001 |
5 min | −0.22 ± 0.11 | .05 | −0.20 ± 0.11 | .07 | −0.15 ± 0.11 | .18 | −0.06 ± 0.13 | .67 |
10 min | −0.14 ± 0.08 | .09 | −0.14 ± 0.08 | .08 | −0.10 ± 0.08 | .20 | −0.06 ± 0.10 | .51 |
15 min | −0.14 ± 0.06 | .02 | −0.14 ± 0.06 | .01 | −0.12 ± 0.06 | .04 | −0.09 ± 0.08 | .25 |
20 min | −0.12 ± 0.03 | <.001 | −0.12 ± 0.03 | <.001 | −0.11 ± 0.03 | <.001 | −0.10 ± 0.03 | .002 |
40 min | −0.09 ± 0.03 | .001 | −0.09 ± 0.03 | .001 | −0.08 ± 0.03 | .005 | −0.06 ± 0.03 | .05 |
60 min | −0.09 ± 0.02 | <.001 | −0.09 ± 0.02 | <.001 | −0.09 ± 0.02 | <.001 | −0.08 ± 0.02 | <.001 |
80 min | −0.10 ± 0.02 | <.001 | −0.11 ± 0.02 | <.001 | −0.11 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 |
100 min | −0.09 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 | −0.09 ± 0.02 | <.001 |
120 min | −0.09 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 | −0.10 ± 0.02 | <.001 |
HOMA-IR | −3.32 ± 0.56 | <.001 | −3.21 ± 0.55 | <.001 | −3.06 ± 0.56 | <.001 | −2.70 ± 0.63 | <.001 |
Integrated glucose area | −0.001 ± 0.0003 | <.001 | −0.001 ± 0.0003 | <.001 | −0.001 ± 0.0003 | <.001 | −0.001 ± 0.0003 | <.001 |
Integrated insulin area | −0.001 ± 0.0002 | <.001 | −0.001 ± 0.0002 | <.001 | −0.001 ± 0.0002 | <.001 | −0.001 ± 0.0002 | <.001 |
Matsuda index | 2.02 ± 0.26 | <.001 | 2.04 ± 0.25 | <.001 | 1.98 ± 0.25 | <.001 | 2.00 ± 0.30 | <.001 |
Notes: CSA = cross-sectional area; HOMA-IR = homeostasis model assessment of insulin resistance; OGTT = oral glucose tolerance test.
Model 1: adjusted for demographics (age, sex, race); model 2: adjusted for model 1 + height; model 3: adjusted for model 2 + physical activity (high intensity and walking); model 4: adjusted for model 3 + neuropathy (peroneal motor nerve conduction velocity).